Zhao Wang
Beijing, Beijing Municipality, 100050, China
NCT Number: NCT06131489
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 100050, China
Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Time frame: 4 Week
The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.
Time frame: 1 month
Incidence of adverse reactions
Time frame: 1 years
Overall survival rate
Contact information is provided by the study sponsor or research team.
Beijing Friendship Hospital
Other
Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05775705
DNA Virus Infections, Epstein-Barr Virus
Beijing, Beijing Municipality, China
View Trial DetailsNCT01494103
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Houston, Texas, United States
View Trial DetailsNCT07497438
Cytokine Release Syndrome, Hemic and Lymphatic Diseases
Bobigny, France
View Trial DetailsNCT01652092
Albinism, Bare Lymphocyte Syndrome
Minneapolis, Minnesota, United States
View Trial Details